About Our Team

The Mercy Story

The kernel of Mercy BioAnalytics was sown when Paul Blavin, financier and philanthropist, met a brilliant freshman enrolled in the Blavin Scholars Program at the University of Michigan. That young man was Joseph Sedlak.

With Paul’s support, Joseph graduated summa cum laude from the University of Michigan with a degree in biomedical engineering, entered Harvard Medical School, and along the way became Paul’s adopted son. Through his studies at labs across Harvard and MIT, Joseph’s interest was piqued when he recognized the largest unmet need in oncology was the early detection of cancer.

As a young scientist comfortable with new concepts, such as nanotechnology and single cell analysis, Joseph developed the novel idea on which he founded Mercy BioAnalytics with Paul in 2018: using single extracellular vesicles for early cancer detection. The company leverages Paul’s business savvy and connections with Joseph’s scientific curiosity in its mission to improve the lives of patients suffering from cancer.

Paul and Joseph have gathered around them a stellar group of advisors and colleagues with decades of experience and success in cancer detection and diagnostics who share their mission.

The Mercy Story

The kernel of Mercy BioAnalytics was sown when Paul Blavin, financier and philanthropist, met a brilliant freshman enrolled in the Blavin Scholars Program at the University of Michigan. That young man was Joseph Sedlak.

With Paul’s support, Joseph graduated summa cum laude from the University of Michigan with a degree in biomedical engineering, entered Harvard Medical School, and along the way became Paul’s adopted son. Through his studies at labs across Harvard and MIT, Joseph’s interest was piqued when he recognized the largest unmet need in oncology was the early detection of cancer.

As a young scientist comfortable with new concepts, such as nanotechnology and single cell analysis, Joseph developed the novel idea on which he founded Mercy BioAnalytics with Paul in 2018: using single extracellular vesicles for early cancer detection. The company leverages Paul’s business savvy and connections with Joseph’s scientific curiosity in its mission to improve the lives of patients suffering from cancer.

Paul and Joseph have gathered around them a stellar group of advisors and colleagues with decades of experience and success in cancer detection and diagnostics who share their mission.

Team Mercy

Paul Blavin

Paul Blavin

Co-Founder, Chief Executive Officer

Eric Huang, PhD

Eric Huang, PhD

Chief Scientific Officer

Emily Winn-Deen, PhD

Emily Winn-Deen, PhD

Sr. Vice President of Diagnostics Strategy

John Cavanaugh

John Cavanaugh

Vice President of Clinical Affairs

Britt Derrien

Britt Derrien

Chief of Staff

Laura Bortolin, PhD

Laura Bortolin, PhD

Co-Director of Research & Development

Daniel Salem, PhD

Daniel Salem, PhD

Co-Director of Research & Development

Anthony Couvillon, PhD

Anthony Couvillon, PhD

Sr. Scientist, Head of Antibody Discovery

Daniel Gusenleitner, PhD

Daniel Gusenleitner, PhD

Head of Computational Biology

Joseph Sedlak

Joseph Sedlak

Scientific Founder, Advisor

Barry Berger, MD

Barry Berger, MD

Lead Medical Advisor

Vera Imper, PhD

Vera Imper, PhD

Senior Advisor, Corporate Development

Kelly Biette, PhD

Kelly Biette, PhD

Sr. Computational Biologist

Stephen Brinton

Stephen Brinton

Bioinformatics Manager

Turgut Fettah Kosar, PhD, ALM

Turgut Fettah Kosar, PhD, ALM

Director of Laboratory Operations

Jason Millette

Jason Millette

Lead Architect, Cloud and Infrastructure

Ibukun Zabroski, PhD

Ibukun Zabroski, PhD

Scientist

Sanchari Banerjee, PhD

Sanchari Banerjee, PhD

Scientist

Jonian Grosha, PhD

Jonian Grosha, PhD

Scientist

Chris Sedlak

Chris Sedlak

Research & Development Engineer

Delaney Byrne

Delaney Byrne

Associate Scientist

MacKenzie King

MacKenzie King

Research Associate

Peter Duff

Peter Duff

Research Associate

Bilal Hamzeh

Bilal Hamzeh

Research Associate

Amy Blavin

Amy Blavin

Director of Guest Experiences

Since Mercy’s inception in April 2018, we have been inspired by the old African Proverb:

“If you want to go fast, go alone.
If you want to go far, go together.”

We are humbled and grateful to have locked arms with a world-class group of scientists, clinicians and diagnostic business leaders, all passionate and determined to save lives by detecting cancer early when it is most curable.

Board of Directors

Stanley Lapidus

Stanley Lapidus

Chairman

Paul Meister

Paul Meister

Sonja Hoel Perkins

Sonja Hoel Perkins

Paul Blavin

Paul Blavin

Joseph Sedlak

Joseph Sedlak

Strategic Advisors

Randy Schekman, PhD

Randy Schekman, PhD

Scientific Advisor

Ted Snelgrove

Ted Snelgrove

Sr Executive Advisor

Ellen Goldberg

Ellen Goldberg

Marketing

Floyd Taub, MD

Floyd Taub, MD

Sr Executive Advisor

Alberto Gutierrez, PhD

Alberto Gutierrez, PhD

Regulatory Affairs

Clinical Collaborators

Beth Karlan, MD

Beth Karlan, MD

Charles “Chip” Landen, MD

Charles “Chip” Landen, MD

Bo Rueda, PhD

Bo Rueda, PhD

Amy Bregar, MD

Amy Bregar, MD

World Leaders in Clinical Trials

World renowned advisors with over 100 years of combined experience designing and conducting the most prominent clinical trials for the early detection of cancer.

David Ransohoff, MD

David Ransohoff, MD

Steven Skates, PhD

Steven Skates, PhD

Christine Berg, MD

Christine Berg, MD

“Never doubt that a small group of thoughtful, committed citizens can change the world; indeed, it’s the only thing that ever has.”

– Margaret Mead

Unparalleled Innovation.

Real collaboration.

Join Mercy BioAnalytics on our lifesaving mission to detect cancer early when it is most curable

ACCELERATING CLINICAL TRIALS

For pharmaceutical companies, Mercy Halo offers a way to accelerate clinical development programs through retrospective sample analysis, patient screening and clinical trial enrollment, and companion diagnostic development to support commercialization of new drugs.

Mercy BioAnalytics works for companies who want to increase the chances of a drug’s success in clinical trials. Mercy Halo helps identify patients whose cancer has the right molecular profile for their clinical program, monitor their response to investigational drugs or combinations of drugs, and perform retrospective analyses on plasma samples in storage.